Skip to main content
8462 search results for:

Cetuximab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Cetuximab | News

    Cetuximab/irinotecan

    Hypocalcaemia
  2. 01-03-2024 | Cetuximab | News

    Cetuximab

    Hypothyroidism, pneumonitis and rash
  3. 01-03-2024 | Cetuximab | News

    Cetuximab

    Acute-coronary-syndrome
  4. 25-01-2024 | Bevacizumab | Erratum

    Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis

  5. 01-12-2023 | Cetuximab | News

    Cetuximab/nivolumab

    Lack of efficacy and pustular skin rash on the face, chest and scalp: case report
  6. Open Access 29-01-2024 | Cetuximab | OriginalPaper

    Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

    Head and neck squamous cell carcinoma (HNSCC) is the most common malignancy affecting the upper aerodigestive tract [ 1 ]. In 2018, there were approximately 880,000 new diagnoses of head and neck cancers in the world, with one-third of these …

  7. 01-10-2023 | Cetuximab | News

    Cetuximab/fluorouracil

    Portal vein thrombosis: case report
  8. Open Access 01-12-2023 | Cetuximab | OriginalPaper

    Local ocular safety of the subconjunctival injection of cetuximab in rabbits

    OSSN (ocular surface squamous neoplasia) is the most prevalent ocular surface tumor and the third most frequent ocular malignancy in adult population [ 1 ]. Currently, the term OSSN is widely used to include a spectrum of lesions ranging from CIN …

  9. 01-07-2023 | Cetuximab | News

    Cetuximab/encorafenib

    Lack of efficacy: case report
  10. 01-10-2023 | Cetuximab | News

    Cetuximab-sarotalocan

    Infusion related reaction: case report
  11. Open Access 01-12-2023 | Cetuximab | OriginalPaper

    RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

    Epidermal growth factor receptor (EGFR) is an important biomarker for non-small cell lung cancer (NSCLC). Several molecular-targeted agents have been developed and studied to inhibit EGFR activity in oncology therapy [ 1 ]. Despite improvements in …

  12. Open Access 01-12-2023 | Anaphylaxis | OriginalPaper

    Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

    Cetuximab, a chimeric mouse/human monoclonal antibody, is an Epidermal Growth Factor Receptor (EGFR) inhibitor developed in the early 2000s for the treatment of patients with metastatic colorectal or head and neck cancer. The high frequency of …

  13. 01-03-2023 | Laryngoscopy | News

    Cetuximab/nivolumab/paclitaxel

    Infusion reaction and lack of efficacy: case report
  14. Open Access 01-12-2023 | Oral Cancer | OriginalPaper

    Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas

    Oral cancer represents approximately 2% of all human cancers and is the seventh most common cancer overall in the world [ 1 , 2 ]. Along with extended life expectancy, the incidence of multicentric oral cancer is increasing, and hence treatment …

  15. 01-02-2023 | Cetuximab | News

    Cetuximab/panitumumab

    Skin toxicity: 2 case reports
  16. 01-02-2023 | Neck Stiffness | News

    Cetuximab

    Aseptic meningitis: case report
  17. 13-07-2023 | Cetuximab | OriginalPaper

    Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients

    Cetuximab is a chimeric immunoglobulin (Ig)G1 monoclonal antibody (mAb) that binds specifically to the epidermal growth factor receptor (EGFR). It has been approved in the treatment of metastatic colorectal cancer (mCRC) wild-type RAS status. The …

  18. 23-08-2023 | Cetuximab | Online First

    Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer

    Colorectal cancer (CRC) is the third-most common cancer in men and the second-most common cancer in women [ 1 ]. One of the most important molecular targets in the tumourigenesis of CRC is the epidermal growth factor receptor (EGFR) pathway. EGFR …

  19. Open Access 11-10-2023 | Panitumumab | OriginalPaper

    Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada

    Colorectal cancer is the second-leading cause of cancer death in Canada, with projected deaths of 9400 in 2022 [ 1 ]. Survival among patients with de novo or relapsed metastatic disease has improved over time [ 2 , 3 ], but remains relatively low [ …4

  20. 01-11-2022 | Cetuximab | News

    Cetuximab/imatinib/sunitinib

    Acquired resistance: 3 case reports

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.